Objective This study aimed to analyze the clinical efficacy of the Jianpi Shengxue tablet for treating renal anemia.Methods A total of 200 patients with renal anemia from December 2020 to December 2022 were enrolled a...Objective This study aimed to analyze the clinical efficacy of the Jianpi Shengxue tablet for treating renal anemia.Methods A total of 200 patients with renal anemia from December 2020 to December 2022 were enrolled and randomly divided into two groups.Patients in the control group were treated with polysaccharide-iron complex,and those in the experimental group were administered Jianpi Shengxue tablet.After 8 weeks of continuous treatment,the therapeutic outcomes regarding anemia were compared between the two groups.Results After treatment,the red blood cell(RBC)count,hematocrit(HCT),reticulocyte percentage(RET),ferritin(SF),serum iron(SI),transferrin saturation(TSAT),and serum albumin(ALB)all increased(P<0.01),and the clinical symptom score and total iron binding capacity decreased(P<0.01)in the experimental group.Moreover,the improvements in RBC,HCT,RET,SF,SI,TAST,ALB,and clinical symptoms(fatigue,anorexia,dull skin complexion,numbness of hands and feet)in the experimental group were significantly greater than those in the control group(P<0.05).The total effective rate for treating renal anemia was significantly higher in the experimental group than in the control group(P<0.01).Conclusion The Jianpi Shengxue tablet demonstrates efficacy in treating renal anemia,leading to significant improvements in the laboratory examination results and clinical symptoms of patients with renal anemia.展开更多
基金financially supported by the National Natural Science Foundation of China(No.82170701).
文摘Objective This study aimed to analyze the clinical efficacy of the Jianpi Shengxue tablet for treating renal anemia.Methods A total of 200 patients with renal anemia from December 2020 to December 2022 were enrolled and randomly divided into two groups.Patients in the control group were treated with polysaccharide-iron complex,and those in the experimental group were administered Jianpi Shengxue tablet.After 8 weeks of continuous treatment,the therapeutic outcomes regarding anemia were compared between the two groups.Results After treatment,the red blood cell(RBC)count,hematocrit(HCT),reticulocyte percentage(RET),ferritin(SF),serum iron(SI),transferrin saturation(TSAT),and serum albumin(ALB)all increased(P<0.01),and the clinical symptom score and total iron binding capacity decreased(P<0.01)in the experimental group.Moreover,the improvements in RBC,HCT,RET,SF,SI,TAST,ALB,and clinical symptoms(fatigue,anorexia,dull skin complexion,numbness of hands and feet)in the experimental group were significantly greater than those in the control group(P<0.05).The total effective rate for treating renal anemia was significantly higher in the experimental group than in the control group(P<0.01).Conclusion The Jianpi Shengxue tablet demonstrates efficacy in treating renal anemia,leading to significant improvements in the laboratory examination results and clinical symptoms of patients with renal anemia.
文摘目的:研究沙棘柴术胶囊治疗单纯性肥胖症的疗效及其对性激素睾酮(testosterone,T)、黄体生成素/促卵泡激素(luteinizing hormone/follicle-stimulating hormone,LH/FSH)的影响。方法:采用随机、双盲、平行对照的试验设计方法,选取120例女性成人体质指数(body mass index,BMI)≥30的单纯性肥胖自愿受试患者,按照1:1的比例进行随机分组,试验组与对照组各60例,试验组服用沙棘柴术胶囊,对照组服用安慰剂,疗程60天。试验过程中试验组脱落2例,对照组脱落3例。试验结束揭盲后,分析沙棘柴术胶囊治疗单纯性肥胖症的疗效以及对性激素T、LH/FSH比值的影响。结果:试验组患者试验前后体质量、BMI、腰围、臀围、皮下脂肪厚度(B、C、D点)、体脂含量等均低于试验前,差异具有统计学意义(P<0.05),且T、LH/FSH水平低于对照组,差异具有统计学意义(P<0.05)。结论:沙棘柴术胶囊不仅可以有效治疗肥胖症,还可通过调节性激素T、LH/FSH等水平预防发生多囊卵巢综合征。
文摘目的:观察温胆汤加减联合胆经五输穴放血治疗胆郁痰扰型失眠疗效。方法:使用随机平行对照方法,将46例门诊患者按随机分为两组。对照组23例口服地西泮片,起始剂量每次2.5 mg,1次/d,以后可根据病情增至每次10 mg,1次/d。治疗组23例温胆汤(半夏10 g,枳实15 g,竹茹15 g,陈皮15 g,茯苓25 g,大枣10 g,生姜5 g,炙甘草10 g),加水1000 m L,煎后200 m L,2次/d,100 m L/次,温服;胆经五输穴放血,3 d 1次。对照组与治疗组均连续治疗15 d为1个疗程。观察临床症状、睡眠时间、不良反应。结果:治疗组显效19例,有效3例,无效1例,总有效率95.65%;对照组显效14例,有效4例,无效5例,总有效率78.26%。治疗组疗效优于对照组(P<0.05)。结论:温胆汤联合胆经五输穴放血治疗胆郁痰扰型失眠效果显著,值得在临床上广泛推广。